Anticancer Drug Combination, From Possibility to Principles

Da-Yong Lu and Ting-Ren Lu

School of Life Sciences, Shanghai University, China
College of Science, Shanghai University, China

^*Correspondance to: Da-Yong Lu 

 PDF  Full Text Research Article | Open Access

Abstract:

Advanced stage of cancer patient therapies is unsatisfactory and high-mortality of the disease now. A growing consensus for late-stage cancer patient treatment calls for excellent drug combination in clinical trials. Some progress in this respect has been made worldwide. Despite growing popularity in clinical applications, the anticancer drug combinational rules remain to be discovered and massively applied according to clinical situations and personalized status of cancer patients. In the past decade, we have focused on this matter with watchful eyes and scientific imaginations. This article reiterates these types of cancer managements by providing more matured standards and personalized systems. Future landscapes and insights into cancer drug combinational studies and applications are addressed. In order to update this promising clinical paradigm, some key avenues of therapeutic promotion for anticancer drug combination are highlighted in this article. Experimental or clinical pathways and techniques to update cancer treatment will be carried out in the clinic. A variety of clinical drug selection systems in the future are challenged.

Keywords:

Drug combination; Drug selection; Neoplasm metastasis; Biotherapy; Chemotherapy; Personalized cancer therapy

Cite the Article:

Da-Yong Lu, Ting-Ren Lu. Anticancer Drug Combination, From Possibility to Principles. Clin Oncol. 2024;9:2077..